John Oyler Sells BeOne Medicines Shares

John Oyler, Chief Executive Officer and Director of BeOne Medicines Ltd., reported the sale of 3,410 American Depositary Shares (ADS) on June 23, 2026. The sales were conducted under a mandatory tax withholding provision related to a restricted share unit award agreement, with 1/4th of the securities vesting annually starting June 22, 2022. The transactions occurred at a weighted average price, with individual sales ranging from $272.655 to $275.21 per ADS. These sales represent a disposition of shares, reducing Mr. Oyler's directly held shares to zero ADS. However, he retains significant indirect ownership through various trusts and investment vehicles, including ordinary shares held directly and indirectly. The footnotes clarify that some holdings are in trusts where Mr. Oyler disclaims beneficial ownership, while others are held for his benefit in retirement accounts or for his child's benefit. Each ADS represents 13 ordinary shares.